![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1402481
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¿¹Ãø(-2030³â) : Áö¿ªº° ºÐ¼® - Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚº°Asia Pacific Deep Brain Simulation Market Forecast to 2030 - Regional Analysis - by Product, Application, and End User |
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº 2022³â 9,835¸¸ ´Þ·¯¿¡¼ 2030³â¿¡´Â 1¾ï 8,804¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. 2022-2030³âÀÇ CAGRÀº 8.4%·Î ÃßÁ¤µË´Ï´Ù.
½ÉºÎ³úÀڱؿ¡¼ ±â¼úÀÇ Áøº¸¿Í ½ÂÀÎÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀ» ÃËÁø
·Îº¿ À̽Ä, ´ÙÁß ´ë»ó ÀÚ±Ø, ¹Ì¼¼Àü±Ø ¼³°è °³¼±, ÃæÀü½Ä ÆÞ½º ¹ß»ý±â, °³º°ÈµÈ ´ë»ó ÇÁ·Î±×·¡¹Ö µîÀº ³ú½ÉºÎÀÚ±ØÄ¡·á(DBS)ÀÇ ±â¼ú ¹ßÀü Áß ÇϳªÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀ¸·Î DBS Àåºñ´Â ±âÁ¸ ¹æ½Ä¿¡ ºñÇØ ºÎÀÛ¿ëÀÌ Àû°í, ÆÄŲ½¼º´ ȯÀÚÀÇ È¿°ú¿Í Áõ»ó ¿Ïȸ¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. AbbottÀÇ Infinity Deep Brain Stimulation SystemÀº ȯÀÚÀÇ Áõ»ó °ü¸®¸¦ µ½´Â »õ·Î¿î DBS ±â¼úÀÔ´Ï´Ù. 2020³â 2¿ù¿¡ ¹ßÇ¥µÈ MGM MedicalÀÇ º¸µµÀÚ·á¿¡ µû¸£¸é Ÿ¹Ð³ªµÎÀÇ MGM MedicalÀº °¹ÚÀå¾Ö(OCD)¿¡ ´ëÇÑ Ã¹ ¹øÂ° ³ú½ÉºÎÀڱؿä¹ý Ä¡·áÁ¦·Î¼, È¿À²ÀûÀÌ°í ¸ÂÃã Ä¡·á °ü¸®¸¦ Á¦°øÇÏ°í ºÎÀÛ¿ëÀÇ À§ÇèÀ» ÁÙÀÎ ÃÖÃÊÀÇ ¹«¼± iOS ¼ÒÇÁÆ®¿þ¾î DBS ¸ð¹ÙÀÏ Ç÷§ÆûÀÔ´Ï´Ù.¿¡ ´ëÇÑ ÃÖÃÊÀÇ ³ú½ÉºÎÀڱؿä¹ý(DBS)À» ½ÃÇàÇß½À´Ï´Ù. µû¶ó¼ DBSÀÇ ±â¼ú ¹ßÀüÀº ¿¹Ãø ±â°£ Áß ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÉºÎ ³ú ÀÚ±Ø ½ÃÀå¿¡ ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎÀÚ±ØÄ¡·á ½ÃÀå °³¿ä
Áß±¹Àº ¼¼°è¿¡¼ °¡Àå ¸¹Àº ³ëÀÎ Àα¸¸¦ º¸À¯ÇÑ ±¹°¡·Î, The Lancet¿¡ °ÔÀçµÈ "China's Aging Population: Crisis or Opportunity?"(Áß±¹ÀÇ °í·ÉÈ: À§±âÀΰ¡ ±âȸÀΰ¡?)¶ó´Â Á¦¸ñÀÇ ¿¬±¸ °á°ú¿¡ µû¸£¸é 2019³â¿¡ Áß±¹ÀÇ 60¼¼ ÀÌ»ó ³ëÀÎ Àα¸´Â 2¾ï 5400¸¸ ¸íÀ¸·Î, 2040³â¿¡´Â 4¾ï 200¸¸ ¸íÀ¸·Î Áõ°¡ÇÏ¿© Àüü Àα¸ÀÇ 28%¸¦ ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óÇß½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È´Â ºñ°¨¿°¼º ÁúȯÀÇ À§Çè°ú ºÎ´ãÀÌ Áõ°¡Çϰí ÀÇ·á »çȸº¸ÀåÁ¦µµ¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϱ⠶§¹®¿¡ Áß±¹ÀÇ °øÁߺ¸°Ç¿¡ Áß´ëÇÑ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀÔ´Ï´Ù. ChinaDaily¿¡ µû¸£¸é 2023³â 2¿ù ÇöÀç Áß±¹¿¡´Â ¾à 400¸¸ ¸íÀÇ ÆÄŲ½¼º´ ȯÀÚ°¡ ÀÖÀ¸¸ç, 65¼¼ ÀÌ»ó Àα¸ÀÇ 1.7%°¡ ÆÄŲ½¼º´ Áø´ÜÀ» ¹Þ¾Ò´Ù°í ÇÕ´Ï´Ù. Population, and Nutrition Àú³Î¿¡ °ÔÀçµÈ ¿¬±¸¿¡ µû¸£¸é Áß±¹ÀÇ ¾ËÃ÷ÇÏÀ̸Ӻ´ ȯÀÚ ¼ö´Â 600¸¸ ¸íÀ̸ç, 65¼¼, 75¼¼, 85¼¼ÀÇ Ä¡¸Å ºñÀ²Àº °¢°¢ 5%, 11.5%, 30%ÀÔ´Ï´Ù. ½Ã»ó ÇϺΠÇÙ(STN)ÀÇ ³ú ½ÉºÎ ÀÚ±Ø(DBS)Àº ÆÄŲ½¼ º´(PD) Ä¡·á¿¡ È¿°úÀûÀ̸ç, DBS Çϵå¿þ¾îÀÇ ¹ßÀü°ú ÇÔ²² ¿¬±¸ÀÚµéÀº ¸î °¡Áö »õ·Î¿î ÇÁ·Î±×·¡¹Ö ±â¼úÀ» °³¹ßÇßÀ¸¸ç, ±× Áß ¿ø°Ý ÇÁ·Î±×·¡¹ÖÀº Áß±¹¿¡¼ ³Î¸® »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. Á¦Ç°(PINS Medical, Ltd., Áß±¹ º£ÀÌ¡)À» »ç¿ëÇÏ¿© ÆÄŲ½¼º´ ȯÀÚÀÇ ¿ø°Ý ÇÁ·Î±×·¡¹ÖÀ» ¼öÇàÇß½À´Ï´Ù. ÁøÇ༺ ÆÄŲ½¼º´ ȯÀÚ(15³â ÀÌ»óÀÇ ½Ã°£Àû ½Ã¾ß)¿¡°Ô DBS´Â ¸Å¿ì È¿°úÀûÀÎ Ä¡·á ¿É¼ÇÀ¸·Î ¿©°ÜÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª DBS´Â ´Ù¸¥ ¼±Áø±¹°ú ´Þ¸® º¸ÇèÀÌ Àû¿ëµÇÁö ¾Ê´Â °æ¿ì ȯÀÚ¿¡°Ô Å« °æÁ¦Àû ºÎ´ãÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù. Áß±¹¿¡¼´Â ¼ö¼ú ºñ¿ëÀº ÁַΠȯÀÚÀÇ °Ç° º¸Çè¿¡ ÀÇÇØ º¸ÀåµÇÁö¸¸ DBS Çϵå¿þ¾î ºñ¿ëÀº ºÎºÐÀûÀ¸·Î¸¸ º¸ÀåµÇ±â ¶§¹®¿¡ Áß±¹ ½ÃÀå ¼ºÀå¿¡ °É¸²µ¹ÀÌ µÉ ¼ö ÀÖ½À´Ï´Ù.
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¸ÅÃâ°ú 2030³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå ¼¼ºÐÈ
¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº Á¦Ç°, ¿ëµµ, ÃÖÁ¾»ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.
Á¦Ç°º°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº ½Ì±Û ä³Î ½ÉºÎ³ú Àڱرâ, µà¾ó ä³Î ½ÉºÎ³ú Àڱرâ, ¼ÒÇÁÆ®¿þ¾î¿Í ¾×¼¼¼¸®·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â µà¾ó ä³Î ½ÉºÎ³ú Àڱر⠺ι®ÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.
¿ëµµº°·Î´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº ÆÄŲ½¼º´, ÁøÀü, ±ÙÀ°±äÀåÀÌ»ó, °£Áú, ¾ËÃ÷ÇÏÀ̸Ӻ´, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â ÆÄŲ½¼º´ ºÐ¾ß°¡ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.
ÃÖÁ¾»ç¿ëÀÚº°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº º´¿ø, ½Å°æ°úŬ¸®´Ð, ¿Ü·¡ ¼ö¼ú ¼¾ÅÍ, ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â º´¿ø ºÎ¹®ÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.
±¹°¡º°·Î º¸¸é ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀåÀº Áß±¹, ÀϺ», Àεµ, Çѱ¹ , È£ÁÖ, ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. 2022³â¿¡´Â Áß±¹ ºÎ¹®ÀÌ ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼ ÃÖ´ë Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.
Abbott Laboratories»ç, Beijing PINS Medical Co Ltd»ç, Boston Scientific Corp»ç, Medtronic Plc»ç, SceneRay Co Ltd´Â ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ³ú½ÉºÎ ÀÚ±ØÄ¡·á ½ÃÀå¿¡¼ »ç¾÷À» ¿î¿µÇϰí ÀÖ´Â ´ë±â¾÷ÀÔ´Ï´Ù.
The Asia Pacific deep brain simulation market is expected to grow from US$ 98.35 million in 2022 to US$ 188.04 million by 2030. It is estimated to grow at a CAGR of 8.4% from 2022 to 2030.
Technological Advancements and Approvals in Deep Brain Stimulation Drive Asia Pacific Deep Brain Simulation Market
Robotic implantation, multi-target stimulation, improved microelectrode designs, rechargeable pulse generators, and personalized, targeted programming are among the technological advancements in deep brain stimulation (DBS). Owing to these advancements, DBS devices show fewer side effects and improved efficacy and symptom relief in Parkinson's patients compared to traditional methods. Abbott's Infinity Deep Brain Stimulation System is a technologically advanced new DBS that helps the patients manage their symptoms. It is the first wireless iOS software DBS mobile platform that has offered efficient and personalized therapy management with reduced risk of side effects. According to the MGM Healthcare press release published in February 2020, MGM Healthcare, Tamil Nadu, performed its first deep brain stimulation (DBS) for obsessive-compulsive disorder (OCD). Therefore, technological advancements in DBS are expected to create opportunities for the Asia Pacific deep brain stimulation market during the forecast period.
Asia Pacific Deep Brain Simulation Market Overview
China is home to the world's largest population of older adults. According to a study published in The Lancet titled "China's Aging Population: Crisis or Opportunity?" in 2019, people in China aged 60 or older were ~254 million. By 2040, that number is expected to rise to 402 million, ~28% of the population. These changes have profound public health implications in the country as the risk and burden of noncommunicable diseases increase along with the demand for health and social care systems. Parkinson's disease (PD) is a common neurodegenerative disease in the country. According to ChinaDaily, there were approximately 4 million Parkinson's patients in China as of February 2023, and ~1.7% of people over 65 years have been diagnosed with the disease. According to a study discussed in the Journal of Health, Population, and Nutrition, the number of people with Alzheimer's disease in China is ~6 million, with dementia rates among 65-, 75-, and 85-year-olds being 5%, 11.5%, and 30%, respectively. Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is effective in the treatment of Parkinson's disease (PD). With advancements in DBS hardware, researchers have developed several novel programming technologies, of which remote programming is widely used in China. Since 2018, we have been performing remote programming for patients suffering from PD using PINS products (PINS Medical, Ltd., Beijing, China). For patients with advanced Parkinson's disease (over a 15-year time horizon), DBS is considered to be a highly effective treatment option. However, DBS remains a significant economic burden on the patient when not reimbursed, unlike in any other developed country. In China, the surgery cost is mainly covered by the patient's health insurance, but the cost of DBS hardware is only partially covered, which can hamper the growth of the market in the country.
Asia Pacific Deep Brain Simulation Market Revenue and Forecast to 2030 (US$ Million)
Asia Pacific Deep Brain Simulation Market Segmentation
The Asia Pacific deep brain simulation market is segmented into product, application, end user, and country.
Based on product, the Asia Pacific deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. In 2022, the dual channel deep brain stimulator segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on application, the Asia Pacific deep brain simulation market is segmented into Parkinson's disease, tremor, dystonia, epilepsy, Alzheimer's disease, and others. In 2022, the Parkinson's disease segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on end user, the Asia Pacific deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. In 2022, the hospitals segment registered the largest share in the Asia Pacific deep brain simulation market.
Based on country, the Asia Pacific deep brain simulation market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. In 2022, China segment registered the largest share in the Asia Pacific deep brain simulation market.
Abbott Laboratories, Beijing PINS Medical Co Ltd, Boston Scientific Corp, Medtronic Plc, and SceneRay Co Ltd are some of the leading companies operating in the Asia Pacific deep brain simulation market.